NASDAQ:MGENMiragen Therapeutics Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Miragen Therapeutics Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $0.99 -0.16 (-13.95 %) (As of 05/29/2020 04:00 PM ET) Add Compare Share Today's Range$0.90Now: $0.99▼$1.1050-Day Range$0.42MA: $0.60▼$1.1552-Week Range$0.31Now: $0.99▼$2.57Volume3.66 million shsAverage Volume1.14 million shsMarket Capitalization$52.39 millionP/E RatioN/ADividend YieldN/ABeta2.06 ProfileAnalyst RatingsAdvanced ChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsSocial Media Miragen Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in discovering and developing proprietary RNA-targeted therapies with a specific focus on microRNAs and their role in diseases where there is a high unmet medical need. Its three lead product candidates include cobomarsen, an inhibitor of miR-155 for treating various blood cancers, such as cutaneous T-cell lymphoma, adult T-cell lymphoma/leukemia, diffuse large B-cell lymphoma, and chronic lymphocytic leukemia; Remlarsen, a replacement for miR-29, a microRNA that is found at abnormally low levels in various pathological fibrotic conditions, including cutaneous, ocular, and idiopathic pulmonary fibrosis; and MRG-110, an inhibitor of miR-92, a microRNA expressed in endothelial cells for the treatment of heart failure, as well as surgical incisions in high risk populations, severe lacerations, and severe burns in the United States and Japan. The company has a license and collaboration agreement with Les Laboratoires Servier and Institut de Recherches Servier for the development of MRG-110. Miragen Therapeutics, Inc. was founded in 2006 and is based in Boulder, Colorado.Read More Beat the Market (BTM) Rank™ 3.3 Analyst's Opinion Consensus RatingMiragen Therapeutics has received a consensus rating of Buy. The company's average rating score is 2.67, and is based on 2 buy ratings, 1 hold rating, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $4.50, Miragen Therapeutics has a potential upside of 355.9% from its current price of $0.99.Amount of Analyst CoverageMiragen Therapeutics has only been the subject of 2 research reports in the past 90 days. Previous Next 2.7 Community Rank Outperform VotesMiragen Therapeutics has received 254 “outperform” votes. (Add your “outperform” vote.)Underperform VotesMiragen Therapeutics has received 220 “underperform” votes. (Add your “underperform” vote.)Community SentimentMiragen Therapeutics has received 53.59% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Miragen Therapeutics and other stocks. Vote “Outperform” if you believe MGEN will outperform the S&P 500 over the long term. Vote “Underperform” if you believe MGEN will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldMiragen Therapeutics does not currently pay a dividend.Dividend GrowthMiragen Therapeutics does not have a long track record of dividend growth. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Miragen Therapeutics insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 3.00% of the stock of Miragen Therapeutics is held by insiders.Percentage Held by InstitutionsOnly 21.37% of the stock of Miragen Therapeutics is held by institutions. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Miragen Therapeutics are expected to grow in the coming year, from ($0.56) to ($0.42) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Miragen Therapeutics is -0.87, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Miragen Therapeutics is -0.87, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioMiragen Therapeutics has a P/B Ratio of 1.94. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next Analyst Opinion: 3.3Community Rank: 2.7Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -Overall Beat the Market Rank™1.33 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Medical laboratories Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:MGEN Previous Symbol CUSIPN/A CIK1590750 Webwww.signalgenetics.com Phone720-643-5200Debt Debt-to-Equity Ratio0.13 Current Ratio4.43 Quick Ratio4.43Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$4.46 million Price / Sales11.75 Cash FlowN/A Price / Cash FlowN/A Book Value$0.51 per share Price / Book1.94Profitability EPS (Most Recent Fiscal Year)($1.34) Net Income$-41,870,000.00 Net Margins-778.69% Return on Equity-154.14% Return on Assets-97.61%Miscellaneous Employees77 Outstanding Shares53,080,000Market Cap$52.39 million Next Earnings Date8/5/2020 (Estimated) OptionableNot Optionable NASDAQ:MGEN Rates by TradingView Receive MGEN News and Ratings via Email Sign-up to receive the latest news and ratings for MGEN and its competitors with MarketBeat's FREE daily newsletter. Miragen Therapeutics (NASDAQ:MGEN) Frequently Asked Questions How has Miragen Therapeutics' stock been impacted by COVID-19 (Coronavirus)? Miragen Therapeutics' stock was trading at $0.6119 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, MGEN stock has increased by 61.3% and is now trading at $0.9870. View which stocks have been most impacted by Coronavirus. Do Wall Street analysts recommend investors buy shares of Miragen Therapeutics? 3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Miragen Therapeutics in the last year. There are currently 1 hold rating and 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Miragen Therapeutics. When is Miragen Therapeutics' next earnings date? Miragen Therapeutics is scheduled to release its next quarterly earnings announcement on Wednesday, August 5th 2020. View our earnings forecast for Miragen Therapeutics. How were Miragen Therapeutics' earnings last quarter? Miragen Therapeutics Inc (NASDAQ:MGEN) posted its earnings results on Thursday, May, 7th. The medical research company reported ($0.18) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.19) by $0.01. The medical research company had revenue of $0.83 million for the quarter, compared to analysts' expectations of $0.78 million. Miragen Therapeutics had a negative return on equity of 154.14% and a negative net margin of 778.69%. View Miragen Therapeutics' earnings history. What price target have analysts set for MGEN? 3 brokerages have issued 12-month target prices for Miragen Therapeutics' stock. Their forecasts range from $3.00 to $6.00. On average, they expect Miragen Therapeutics' share price to reach $4.50 in the next twelve months. This suggests a possible upside of 355.9% from the stock's current price. View analysts' price targets for Miragen Therapeutics. Has Miragen Therapeutics been receiving favorable news coverage? News headlines about MGEN stock have been trending negative recently, according to InfoTrie Sentiment. The research firm scores the sentiment of press coverage by analyzing more than six thousand news and blog sources in real time. The firm ranks coverage of companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Miragen Therapeutics earned a news impact score of -2.6 on InfoTrie's scale. They also assigned media coverage about the medical research company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an effect on the stock's share price in the immediate future. View the latest news aboutMiragen Therapeutics. Who are some of Miragen Therapeutics' key competitors? Some companies that are related to Miragen Therapeutics include DermTech (DMTK), Enzo Biochem (ENZ), Celcuity (CELC), Anpac Bio-Medical Science (ANPC), Biocept (BIOC), Psychemedics (PMD), OpGen (OPGN), PotNetwork (POTN), Avant Diagnostics (AVDX), CBA Florida (CBAI), Cancer Genetics (CGIX), First Choice Healthcare Solutions (FCHS) and Aeon Global Health (AGHC). View all competitors. What other stocks do shareholders of Miragen Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Miragen Therapeutics investors own include Amplify Energy (AMPY), Amplify Energy (AMPY), ADMA Biologics (ADMA), Titan Pharmaceuticals (TTNP), Matinas BioPharma (MTNB), Unum Therapeutics (UMRX), Pennsylvania R.E.I.T. (PEI), Trevena (TRVN), Zosano Pharma (ZSAN) and Chesapeake Energy (CHK). Who are Miragen Therapeutics' key executives? Miragen Therapeutics' management team includes the following people: Dr. William Stuart Marshall Ph.D., Co-Founder, Pres, CEO & Director (Age 55)Mr. Adam Scott Levy, Chief Bus. Officer (Age 41)Dr. Paul D. Rubin, Exec. VP of R&D (Age 65)Eric N. Olson, Co-Founder & Chairman of Scientific Advisory BoardDr. Michael R. Bristow, Co-Founder & Member of the Scientific Advisory Board (Age 74) What is Miragen Therapeutics' stock symbol? Miragen Therapeutics trades on the NASDAQ under the ticker symbol "MGEN." Who are Miragen Therapeutics' major shareholders? Miragen Therapeutics' stock is owned by many different retail and institutional investors. Top institutional shareholders include BlackRock Inc. (0.83%) and Squarepoint Ops LLC (0.13%). View institutional ownership trends for Miragen Therapeutics. Which institutional investors are buying Miragen Therapeutics stock? MGEN stock was bought by a variety of institutional investors in the last quarter, including Squarepoint Ops LLC, and BlackRock Inc.. View insider buying and selling activity for Miragen Therapeutics. How do I buy shares of Miragen Therapeutics? Shares of MGEN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is Miragen Therapeutics' stock price today? One share of MGEN stock can currently be purchased for approximately $0.99. How big of a company is Miragen Therapeutics? Miragen Therapeutics has a market capitalization of $52.39 million and generates $4.46 million in revenue each year. The medical research company earns $-41,870,000.00 in net income (profit) each year or ($1.34) on an earnings per share basis. Miragen Therapeutics employs 77 workers across the globe. What is Miragen Therapeutics' official website? The official website for Miragen Therapeutics is www.signalgenetics.com. How can I contact Miragen Therapeutics? Miragen Therapeutics' mailing address is 6200 LOOKOUT ROAD, BOULDER CO, 80301. The medical research company can be reached via phone at 720-643-5200 or via email at [email protected] This page was last updated on 6/1/2020 by MarketBeat.com Staff
